Back to Search
Start Over
FDA accelerated approval benefits glioblastoma.
- Source :
-
The Lancet. Oncology [Lancet Oncol] 2010 Dec; Vol. 11 (12), pp. 1120. - Publication Year :
- 2010
- Subjects :
- Angiogenesis Inhibitors therapeutic use
Antibodies, Monoclonal, Humanized
Bevacizumab
Dacarbazine therapeutic use
Humans
Temozolomide
United States
Antibodies, Monoclonal therapeutic use
Antineoplastic Agents therapeutic use
Dacarbazine analogs & derivatives
Drug Approval
Glioblastoma drug therapy
United States Food and Drug Administration
Subjects
Details
- Language :
- English
- ISSN :
- 1474-5488
- Volume :
- 11
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- The Lancet. Oncology
- Publication Type :
- Editorial & Opinion
- Accession number :
- 21126686
- Full Text :
- https://doi.org/10.1016/S1470-2045(10)70269-2